estrone has been researched along with Hot Flashes in 20 studies
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
Hot Flashes: A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In two laboratory mammary cancer models, the combination of the aromatase inactivator exemestane plus tamoxifen gives a higher response rate than is found with either agent alone." | 6.71 | Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. ( Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR, 2005) |
| "The aim of this study was to describe the changes in symptom interference during the menopausal transition (MT) stages and early postmenopause (PM), including the effects of age, MT-related factors (estrone, follicle-stimulating hormone, testosterone, MT stages), symptoms (hot flashes, depressed mood, awakening during the night, anxiety, backache, joint pain, forgetfulness, and difficulty concentrating), health-related factors (perceived health), and stress-related factors (perceived stress, cortisol)." | 3.77 | Symptom interference with work and relationships during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. ( Mitchell, ES; Woods, NF, 2011) |
| "To determine whether hot flashes, depressed mood, sleep, cognitive and sexual symptoms correlate with urinary follicle-stimulating hormone (FSH), estrone (E(1)G), and testosterone (T) and with each other during the menopausal transition and early postmenopause (PM)." | 3.74 | Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women's Health Study. ( Mitchell, ES; Percival, DB; Smith-Dijulio, K; Tao, EY; Taylor, HJ; Woods, NF, 2007) |
| "The aims of this study were to examine the association of smoking with the occurrence, frequency, and severity of hot flashes and to determine whether the mechanism by which active cigarette smoking increases the risk of hot flashes is by lowering estradiol and estrone levels." | 3.73 | Cigarette smoking, estrogen levels, and hot flashes in midlife women. ( Babus, J; Flaws, JA; Gallicchio, L; Lewis, LM; Miller, SR; Visvanathan, K; Zacur, H, 2006) |
| "We recruited 177 post-menopausal women to register hot flashes, vaginal dryness, depression, anxiety, sleep alterations, and serum hormones (FSH, LH, estrone, and estradiol)." | 3.72 | The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women. ( Malacara, JM; Martínez-Garza, S; Pérez-Luque, EL; Sánchez-Marín, FJ, 2004) |
| " Bioavailability of sulfated estrogens may contribute to relief of night sweats." | 2.87 | SLCO1B1 genetic variation and hormone therapy in menopausal women. ( de Andrade, M; Dudenkov, T; Faubion, SS; Kapoor, E; Miller, VM; Moyer, AM; Weinshilboum, RM, 2018) |
| "Glycogen was measured fluorometrically in swab eluate." | 2.84 | Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. ( Blair, IA; Cohen, L; Fiedler, T; Fredricks, DN; Freeman, EW; Guthrie, KA; Hoffman, NG; Joffe, H; LaCroix, AZ; Liu, C; Mitchell, CM; Munch, M; Newton, K; Reed, SD; Srinivasan, S; Wu, MC; Zhan, X, 2017) |
| "In two laboratory mammary cancer models, the combination of the aromatase inactivator exemestane plus tamoxifen gives a higher response rate than is found with either agent alone." | 2.71 | Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. ( Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR, 2005) |
| "Measurements of a bone resorption marker, i." | 2.69 | Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women. ( Baracat, E; Dey, M; Haidar, M; Lopez, FJ; Negro-Vilar, A; Pickar, J, 1999) |
| "The experience of hot flashes is characterized by significant inter- and intra-individual variability among women." | 1.35 | Association of various dimensions of hot flashes with systemic levels of gonadal steroids. ( Brown, K; Jenschke, M; Miller, V; Ratka, A; Simpkins, J, 2009) |
| " One ring designated as PI-002 (n = 8) delivered in vitro estradiol 160 microg/day and progesterone 20 mg/day, while the other (PI-003; n = 12) delivered the same dosage of estradiol but only half the progesterone (10 mg/day)." | 1.32 | Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. ( Hamada, AL; Johansson, E; Maruo, T; Nash, H; Samoto, T; Spitz, IM; Yoshida, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitchell, CM | 1 |
| Srinivasan, S | 1 |
| Zhan, X | 1 |
| Wu, MC | 1 |
| Reed, SD | 1 |
| Guthrie, KA | 1 |
| LaCroix, AZ | 1 |
| Fiedler, T | 1 |
| Munch, M | 1 |
| Liu, C | 1 |
| Hoffman, NG | 1 |
| Blair, IA | 1 |
| Newton, K | 1 |
| Freeman, EW | 1 |
| Joffe, H | 2 |
| Cohen, L | 1 |
| Fredricks, DN | 1 |
| Moyer, AM | 1 |
| de Andrade, M | 1 |
| Faubion, SS | 1 |
| Kapoor, E | 1 |
| Dudenkov, T | 1 |
| Weinshilboum, RM | 1 |
| Miller, VM | 1 |
| Lobo, RA | 1 |
| Liu, J | 1 |
| Stanczyk, FZ | 1 |
| Constantine, GD | 1 |
| Pickar, JH | 1 |
| Shadiack, AM | 1 |
| Bernick, B | 1 |
| Mirkin, S | 1 |
| Crawford, S | 1 |
| Economou, N | 1 |
| Kim, S | 1 |
| Regan, S | 1 |
| Hall, JE | 1 |
| White, D | 1 |
| Woods, NF | 4 |
| Cray, L | 1 |
| Mitchell, ES | 4 |
| Herting, JR | 1 |
| Ratka, A | 1 |
| Miller, V | 1 |
| Brown, K | 1 |
| Jenschke, M | 1 |
| Simpkins, J | 1 |
| Tuomikoski, P | 1 |
| Haapalahti, P | 1 |
| Ylikorkala, O | 1 |
| Mikkola, TS | 1 |
| Schmidt, PJ | 1 |
| Murphy, JH | 1 |
| Haq, N | 1 |
| Danaceau, MA | 1 |
| St Clair, L | 1 |
| Hamada, AL | 1 |
| Maruo, T | 1 |
| Samoto, T | 1 |
| Yoshida, S | 1 |
| Nash, H | 1 |
| Spitz, IM | 1 |
| Johansson, E | 1 |
| Malacara, JM | 1 |
| Pérez-Luque, EL | 1 |
| Martínez-Garza, S | 1 |
| Sánchez-Marín, FJ | 1 |
| Love, RR | 1 |
| Hutson, PR | 1 |
| Havighurst, TC | 1 |
| Cleary, JF | 1 |
| Raynaud, JP | 1 |
| Lévrier, M | 1 |
| Calaf, J | 1 |
| Laur, C | 1 |
| Pélissier, C | 1 |
| Gallicchio, L | 2 |
| Visvanathan, K | 2 |
| Miller, SR | 2 |
| Babus, J | 2 |
| Lewis, LM | 2 |
| Zacur, H | 2 |
| Flaws, JA | 2 |
| Smith-Dijulio, K | 2 |
| Percival, DB | 2 |
| Tao, EY | 2 |
| Taylor, HJ | 1 |
| Hirvonen, E | 1 |
| Cacciatore, B | 1 |
| Wahlström, T | 1 |
| Rita, H | 1 |
| Wilén-Rosenqvist, G | 1 |
| Baracat, E | 1 |
| Haidar, M | 1 |
| Lopez, FJ | 1 |
| Pickar, J | 1 |
| Dey, M | 1 |
| Negro-Vilar, A | 1 |
| Rebar, RW | 1 |
| Trabal, J | 1 |
| Mortola, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Defining the Vaginal Microbiome and the Vaginal pH of Menopausal Women With and Without Genitourinary Syndrome and With and Without Hormone Replacement Therapy[NCT05122065] | 432 participants (Anticipated) | Observational | 2021-12-01 | Not yet recruiting | |||
| Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance[NCT01116401] | Phase 4 | 29 participants (Actual) | Interventional | 2009-11-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Åsberg Depression Rating Scale is a widely used 10-item clinician-rated scale that describes the severity of depressive symptoms. It has a range of 0-60 with higher scores indicating greater symptom burden. Participants were assessed at baseline and four weeks after the GnRHa injection in order to calculate the change in MADRS score. (NCT01116401)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| GnRH Agonist Injection | 3.1 |
Wake after sleep onset (WASO) is calculated by averaging the number of minutes spent awake after initiating sleep each night from the two ambulatory polysomnography studies conducted at baseline and the two ambulatory polysomnography studies conducted four weeks after the GnRHa injection. (NCT01116401)
Timeframe: baseline and 4 weeks
| Intervention | percent change (Number) |
|---|---|
| GnRH Agonist Injection | 62 |
8 trials available for estrone and Hot Flashes
| Article | Year |
|---|---|
Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Estradiol; Estrone; Female; Glycogen; Hot Flashes; Human | 2017 |
SLCO1B1 genetic variation and hormone therapy in menopausal women.
Topics: Biological Availability; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Estro | 2018 |
Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Topics: Adult; Aged; Biological Availability; Endometrial Hyperplasia; Estradiol; Estrone; Female; Hot Flash | 2019 |
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; A | 2005 |
Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
Topics: Administration, Cutaneous; Adult; Aged; Drug Administration Schedule; Endometrium; Erythema; Estradi | 2005 |
Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.
Topics: Administration, Cutaneous; Aged; Bone Density; Drug Therapy, Combination; Dydrogesterone; Endometriu | 1997 |
Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women.
Topics: Adult; Bone Resorption; Estrogens; Estrone; Female; Hot Flashes; Humans; Middle Aged; Pilot Projects | 1999 |
Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women.
Topics: Double-Blind Method; Endometrial Hyperplasia; Equilin; Estrogen Replacement Therapy; Estrone; Female | 2000 |
12 other studies available for estrone and Hot Flashes
| Article | Year |
|---|---|
A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.
Topics: Adolescent; Adult; Circadian Rhythm; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Gonad | 2013 |
Endocrine biomarkers and symptom clusters during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.
Topics: Adult; Affective Symptoms; Autonomic Nervous System; Cognition Disorders; Estrone; Female; Follicle | 2014 |
Association of various dimensions of hot flashes with systemic levels of gonadal steroids.
Topics: Estrone; Female; Hot Flashes; Humans; Middle Aged; Progesterone | 2009 |
Vasomotor hot flushes and 24-hour ambulatory blood pressure in recently post-menopausal women.
Topics: Blood Pressure; Estradiol; Estrone; Female; Follicle Stimulating Hormone; Heart Rate; Hot Flashes; H | 2010 |
Symptom interference with work and relationships during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study.
Topics: Adult; Anxiety; Biomarkers; Comorbidity; Depression; Estrone; Female; Follicle Stimulating Hormone, | 2011 |
Basal plasma hormone levels in depressed perimenopausal women.
Topics: Adult; Climacteric; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Depression; Estradiol; E | 2002 |
Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women.
Topics: Administration, Intravaginal; Affect; Aged; Endometrium; Estradiol; Estrogen Replacement Therapy; Es | 2003 |
The relationship of estrogen receptor-alpha polymorphism with symptoms and other characteristics in post-menopausal women.
Topics: Anxiety; Bone Density; Cross-Sectional Studies; Depression; Educational Status; Estradiol; Estrogen | 2004 |
Body mass, estrogen levels, and hot flashes in midlife women.
Topics: Age Factors; Body Mass Index; Case-Control Studies; Estradiol; Estrogens; Estrone; Female; Hot Flash | 2005 |
Cigarette smoking, estrogen levels, and hot flashes in midlife women.
Topics: Baltimore; Body Mass Index; Case-Control Studies; Chi-Square Distribution; Educational Status; Estra | 2006 |
Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women's Health Study.
Topics: Adult; Anxiety; Biomarkers; Depression; Estrone; Female; Follicle Stimulating Hormone, Human; Health | 2007 |
Hot flash severity in hormone therapy users/nonusers across the menopausal transition.
Topics: Adult; Estrogen Replacement Therapy; Estrone; Female; Follicle Stimulating Hormone, Human; Hot Flash | 2007 |